Investors

NYSE: ZYME

Price
$ 44.11

Change
$ 0.14 | 0.32%

Volume
262,238

As of January 16, 2020 Close

News

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
1/13/2020
8:30 AM ET
Press Release

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

1/13/2020

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also announced multiple clinical program advances for its lead candidates, ZW25 and ZW49.

 Continue Reading
1/12/2020
10:00 AM ET
Press Release

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

1/12/2020

Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast CancerVANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance® (palbociclib), an oral CDK4/6 inhibitor, and the hormone therapy fulvestrant in patients with previously-treated locally advanced and/or metastatic HER2-positive, HR-positive breast cancer. Zymeworks will sponsor the study, and Pfizer will provide palbociclib.

 Continue Reading
1/7/2020
8:30 AM ET
Press Release

Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

1/7/2020

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT.

 Continue Reading
11/22/2019
2:30 AM ET
Press Release

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

11/22/2019

SINGAPORE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients with HER2‑expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore. Zymeworks and its collaborator BeiGene, Ltd. plan to advance ZW25 into potentially registration-enabling global studies in HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA), based on these durable and consistent clinical data.

 Continue Reading
11/18/2019
8:30 AM ET
Press Release

Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

11/18/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from the Phase 1 clinical trial evaluating the HER2‑targeted bispecific antibody, ZW25, in patients with HER2‑expressing solid tumors for a mini oral presentation at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore.

 Continue Reading
Displaying 1 to 5 (of 134 releases)
Copyright 2020, © S&P Global Market Intelligence  Terms of Use